or have numerous other actions with little relation ship to either of these two processes?
TGF-13 has been identified in many normal tissues. 4 Several growth factors closely related to TGF-13 have also been identified (TGF-131 ' TGF-132 and TGF-(33)' The growth factors comprising the TGF-13 family are now thought to have roles in embryological development and normal physiology, as well as in pathophysiology. TGF-13 is important to wound healing; it is probably a natural mediator of wound healing.
TGF-13 is diffusely distributed in the eye, in the aqueous humour,5.6 conjunctival stroma, ciliary body,7.8 the choroid and retina. 9 TGF-13 is an important factor in many aspects, including the mediation of the healing process in ophthalmic surgery. lO In order to guide the clinical use of TGF-I3, we tested the ocular toxicity of TGF-13 1'
MATERIALS AND METHODS

Drugs
TGF-131 in 20 mM acetate buffer with 0.5% gelatin (100 Bloom, type A) stabiliser (100 Jl.g/ml) and diluent was obtained from Escalon Ophthalmics (Skillman, NJ). It was kept at 4°C and prepared fresh before intravitreous injection. Five different doses (20 j.Lg, 10 j.Lg, 5 j.Lg, 1 j.Lg and 0.5 j.Lg) were used in this study.
Intravitreous Injection
Twenty-eight eyes of New Zealand white rabbits weighing 2-3 kg were used in this study. The rabbits were treated in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Research and were kept on a 12-hour light/12-hour dark cycle.
The eyes were divided into six groups: group 1, 7 eyes given 20 j.Lg TGF-13 1 in 0.2 ml of the stock solution; group 2, 4 eyes given 10 j.Lg TGF-131 in Eye (1996) 10,709-713 © 1996 Royal College of Ophthalmologists 0.1 ml of the stock solution; group 3, 4 eyes given 5 /-Lg TGF-131 in 0.1 ml diluent; group 4, 4 eyes given 1 /-Lg TGF-131 in 0.1 ml diluent; group 5, 4 eyes given 0.5 /-Lg TGF-131 in 0.1 ml diluent; and group 6, 3 eyes given 0.1 ml diluent as control.
The rabbits were anaesthetised with an intramus cular injection of a mixture of ketamine hydrochlor ide (50 mg/kg) and xylazine hydrochloride (5 mg/kg). The pupils were fully dilated with 2.5% phenyleph rine hydrochloride. Before injection, the conjunctiva was sterilised with 5% povidone-iodine and then washed with balanced salt solution. Paracentesis was performed with a 30 gauge needle on a 1 ml tuberculin syringe before intravitreal injection; 0.1-0.2 ml of aqueous humour was drawn out. The different doses of TGF-131 or diluent were then injected into the approximate middle of the vitreous cavity through the pars plana using a 30 gauge needle on a 1 ml tuberculin syringe with the bevelled side of the needle facing anteriorly. Two normal eyes were used for evaluation of the thickness of the cornea and endothelium.
Electroretinography Test
Both before and 10 and 30 days after intravitreal injection, electroretinography (ERG) tests were performed with LKC Technologies UTAS-E 2000 systems for steps 1, 2 and 4. Pupils were dilated with 2.5% phenylephrine hydrochloride and 1% cyclo pentolate hydrochloride. The rabbits were dark adapted for 20 minutes before tests. During tests the rabbits were anaesthetised as described pre viously; the eyes were numbed with 0.5% propar acaine hydrochloride. Unipolar contact lenses were placed on both corneas with some Goniosol ophthal mic solution (IOLAB Pharmaceuticals, Claremont, CA). The negative electrode was inserted subcuta neously in the middle of the forehead and the ground was clipped to the earlobe. Three sweeps were averaged for each step. Steps 1, 2 and 4 were a scotopic white 24 dB single flash, scotopic white 0 dB single flash, and photopic white 0 dB single flash, respectively. After step 2 was performed, rabbits were given 3-5 minutes of light adaptation before proceeding to step 4.
Clinical Observation and Histological Examination
Before injection of the drug, the eyes were examined with the indirect ophthalmoscope and slit lamp and were found to be normal. After injection, the eyes were checked every 2 or 3 days with the slit lamp and indirect ophthalmoscope. At either 10 days or 30 days after intravitreous injection the rabbits were killed with an intracardiac injection of 1 ml pento barbital. Twelve eyes were enucleated at 10 days; 10 eyes were enucleated at 30 days after injection. The eyes were fixed in 2 % paraformaldehyde and 3 % C. LIANG ET AL. glutaraldehyde after enucleation, and then processed for paraffin sectioning, stained with haematoxylin and eosin, and observed under a light microscope.
Four eyes which received 20 /-Lg TGF-131 and two normal eyes were enucleated 5 days after injection; the corneas were removed with a small rim of sclera.
The corneal thickness was compared grossly with the normal cornea. The corneal endothelium was stained with 0.5% trypan blue as described elsewhere ll and the morphology was evaluated under a light micro scope.
RESULTS.
Clinical Findings Groups 1 and 2. Three days after injection, opacity began in the corneas of all the eyes which received 20 /-Lg or 10 /-Lg of TGF-131' Five days after injection, the corneas were diffusely opaque with moderate congestion of the conjunctiva and pannus around the limbus (Fig. 1) . There was no discharge or corneal epithelium defect, and the anterior chamber and fundus were not visible. Ten days later, the corneas were still opaque and no view of the inside of the eye was possible. Two weeks later, corneal opacity had become mild, the fundus was visible, and the retina appeared normal. The cornea was still slightly opaque but the pannus had diminished 30 days later. Group 4. In the 4 eyes which were injected with 1 j.Lg of TGF-l3b 1 cornea was slightly opaque and the other 3 were clear without pannus formation. The fundus of 2 of 4 eyes was not visible during the first week after injection. One week later, the cornea became clear and the fundus was visible; the retina appeared normal.
Group 5. In the 4 eyes which received 0.5 /-Lg TGF-131 the corneas were clear (Fig. 2) after injection but the fundus was slightly hazy in 2 of 4 eyes because of the opacity of the vitreous during the first week after injection. One week later, the vitreous became clear, the fundus was visible and the retina looked normal.
Group 6. In the 3 eyes injected with 0.1 ml diluent as a control, all the corneas were clear after injection; however, the fundus was not visible in 2 of 3 eyes during the first week after injection. One week later, the fundus became clear in all eyes.
The clinical findings are summarised in Table I. TOXICITY OF INTRAVITREOUS TGF-BETA 1 The corneal endothelium showed a regular hexagonal shape (trypan blue stain, original magnification X200). Five days after injection of 0.5 {tg of TGF-f31 the cornea is clear. The corneal endothelium 5 days after injection of 20 {tg TGF-f31. The corneal endothelial cells have lost their hexagonal shape, and they are enlarged and irregular (trypan blue stain, original magnification X200). 
ERG Results
A standard ERG protocol was used. This protocol is the one currently recommended by the International Society of the Clinical Electrophysiology of Vision.
Step 1 is a rod response (dark-adapted, weak stimulus); step 2 is a maximum response to mixed Values are the percentage of preinjection readings. The diluent may cause vitreous opacity but the eye can recover spontaneously within 1 week.
